Dual Incretin
Review
Research edition
October 2026

The publication

The source is part
of the explanation.

Original research October 5, provider reviews October 15, and scientific sources October 21, 2026.

Follow the evidence

Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Scientific articles identify the original reports and labeling examined, with access limits stated in each article. Provider pages document advertised offers.

  1. FDA — Zepbound approval and dual receptor activityHistorical approval announcement; mechanism context
  2. MedlinePlus — tirzepatide injectionFederal patient drug information
  3. Aronne et al. — SURMOUNT-5, NEJM 2025 (PubMed abstract)Randomized trial; abstract reviewed, not full-text appraisal
  4. Frías et al. — SURPASS-2, NEJM 2021 (PubMed abstract)Randomized diabetes trial; abstract reviewed
  5. CoreAge Rx — official treatment pagesProvider offer
  6. CoreAge Rx — tirzepatide offerProvider offer
  7. CoreAge Rx Help Center — Pricing & PlansProvider billing terms
  8. SuperHealthy Rx — current GLP-1 offerProvider offer
  9. Likeness Rx — GLP-1 plans and billingProvider offer
  10. Ro Body — membership and medication costsProvider offer
  11. WeightWatchers — Med+ membership and medicationProvider offer
  12. LillyDirect — pharmacy access and independent care optionsManufacturer access program
  13. FDA — concerns with unapproved GLP-1 drugsRegulator guidance
  14. FDA — compounding questions and answersRegulator guidance
  15. FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
  16. NIDDK — prescription medications for overweight and obesityFederal patient education
  17. Clinical Trial ParticipationPrimary health resource; checked October 5, 2026
  18. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - PubMedPrimary source; original trial abstracts used for trial summaries
  19. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - PubMedPrimary source; original trial abstracts used for trial summaries
  20. Prescription Medications to Treat Overweight & Obesity - NIDDKPrimary health resource; checked October 5, 2026
  21. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - PubMedPrimary health resource; checked October 5, 2026
  22. GLP-1 agonists: MedlinePlus Medical EncyclopediaFederal patient information; checked October 5, 2026
  23. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
  24. Understanding Unapproved Use of Approved Drugs "Off Label"Federal patient information; checked October 5, 2026
  25. Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi HealthProvider public offer; checked October 5, 2026
  26. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  27. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  28. Weight Loss Care for Women, Built to Last | HersProvider public offer; checked October 5, 2026
  29. FAQs | HersProvider public offer; checked October 5, 2026
  30. Frequently Asked Questions (FAQs) | Form HealthProvider public offer; checked October 5, 2026
  31. What is the cost of medication? - Form Health Patient Support CenterProvider public offer; checked October 5, 2026
  32. Ondra Health: Pricing and pharmacy availabilityProvider public information; checked October 15, 2026
  33. Ondra Health: Compounded semaglutide plansProvider public information; checked October 15, 2026
  34. Ondra Health: Compounded tirzepatide plansProvider public information; checked October 15, 2026
  35. Ondra Health: Refund and cancellation policyProvider public information; checked October 15, 2026
  36. Ondra Health: Terms of serviceProvider public information; checked October 15, 2026
  37. Fitish RX: Compounded semaglutide with B6Provider public information; checked October 15, 2026
  38. Fitish RX: Compounded tirzepatide injectionProvider public information; checked October 15, 2026
  39. Fitish RX: Oral tirzepatide tabletsProvider public information; checked October 15, 2026
  40. Fitish RX: Return and exchange policyProvider public information; checked October 15, 2026
  41. Fitish RX: State service descriptionsProvider public information; checked October 15, 2026
  42. Fitish RX: Terms and conditionsProvider public information; checked October 15, 2026
  43. Fitish RX: Care and program FAQProvider public information; checked October 15, 2026
  44. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Full primary post hoc analysis main text and main Table 1 reviewed; supplementary file and original trial protocols not independently reviewed. · Checked 2026-10-21
  45. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Full primary post hoc report, Methods, Results, main Table 1 and Discussion/funding reviewed; supplementary tables and source-trial protocols not separately reviewed. · Checked 2026-10-21
  46. DailyMed: WEGOVY semaglutide current prescribing informationCurrent official DailyMed label, updated June 18, 2026, current archive June 30, 2026; indications, relevant safety sections 5.2, 5.3, 5.5, 5.6, 5.10, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21
  47. DailyMed: ZEPBOUND tirzepatide current prescribing informationCurrent official DailyMed label, updated August 28, 2026, current archive September 2, 2026; indications, relevant safety sections 5.2 through 5.5 and 5.9, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21